Santarus Inc sues Dr Reddy's Laboratories over Generic Zegerid

Dr. Reddys Laboratories Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500124 | NSE: DRREDDY

16 Aug 2012 Evaluate

California-based Santarus Inc along with the University of Missouri, licensor of the Santarus patents, has filed a court case against Dr Reddy's Laboratories, accusing the latter for infringing its patents on heartburn drug Zegerid. The move is in response to the company’s abbreviated new drug application (ANDA)with US Food and Drug Administration, stating its intent to market generic versions of Zegerid before July 2016, when Santarus' patents on the drug expires. Zegerid capsules, which treat heartburn and other symptoms, related to gastroesophageal reflux disease, brought in sales of $10.3 million in the April-June period.

Zegerid has filed for patent infringement case as it has challenged the ruling of US district court and is currently awaiting a decision on the case. In 2010, a Delaware federal court ruled that the patents were invalid because of obviousness in light of prior art. California-based Santarus has reportedly challenged the district court's decision, arguing that the prior art used to invalidate the patents actually taught away from the claimed invention.

On the standalone basis, Dr Reddy's Laboratories posted a fall of 60.87% in its net profit at Rs 177.66 crore for the quarter ended June 30, 2012 as compared to Rs 454.05 crore for the same quarter in the previous year. However, total income has increased by 4.70% at Rs 1834.94 crore for quarter under review as compared to Rs 1752.50 crore for the quarter ended June 30, 2011.

On the consolidated basis, the company has posted a rises of 27.87% in its net profit at Rs 335.98 crore for the quarter ended June 30, 2012 as compared to Rs 262.74 crore for the same quarter in the previous year. Total income has increased by 28.31% at Rs 2562.46 crore for quarter under review as compared to Rs 1997.02 crore for the quarter ended June 30, 2011.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Labs. Share Price

1350.00 21.65 (1.63%)

25-Jun-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1862.15
Dr. Reddys Labs.	1350.00
Cipla	1440.30
Zydus Lifesciences	1101.50
Lupin	2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.